NCT07747246

Completed

Retrospective Study of Romiplostim for Platelet Engraftment ...

Tongji Hospital Source

Compare

Other study identifiers

Sponsor study identifier

DHZ1962-R

Study Type

observational

Actual enrollment (reported)

103

Locations

1 country

Sites

1

Timeline

Study Start

January 1, 2025

Actual (reported)

Primary Completion

May 1, 2026

Actual (reported)

Study Completion

July 15, 2026

Actual (reported)

Brief Summary

This is a retrospective observational study evaluating the efficacy and safety of romiplostim for promoting platelet engraftment in patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at Tongji Hospital Afﬁliated to Tongji Medical College of Huazhong University of Science and Technology between January 2025 to May 2026. Medical records were reviewed to collect data on platelet recovery time, transfusion requirements, and adverse events. The primary endpoint was time to platelet engraftment. Secondary endpoints included platelet recovery kinetics, transfusion requirements, transplant-related complications, and safety outcomes.No interventions were assigned as part of this study.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 103 participants
Study completion date: July 15, 2026
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
January 1, 2025
Actual (reported)
Primary Completion
May 1, 2026
Actual (reported)
Study Completion
July 15, 2026
Actual (reported)
First Submitted
July 27, 2026
Actual (reported)
First Posted
August 5, 2026
Actual (reported)

Last Updated: August 5, 2026
Status Verified: July 2026
Last Update Submitted: July 30, 2026

Conditions

Thrombocytopenia

Outcome Measures

Primary Outcomes (1)

Time to Platelet Recovery to ≥50×10⁹/L
Time from allogeneic hematopoietic stem cell transplantation (Day 0) to the first date of achieving platelet count ≥50×10⁹/L without transfusion support in the preceding 7 days.
up to Day 100

Secondary Outcomes (2)

Time to Platelet Engraftment
up to Day 100
Time to Neutrophil Engraftment
up to Day 60

Study Arms (2)

Romiplostim Group

Patients who received romiplostim after allogeneic hematopoietic stem cell transplantation for platelet engraftment.

Control Group

Patients who did not receive romiplostim after allogeneic hematopoietic stem cell transplantation.

Eligibility Criteria

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients who underwent allo-HSCT at Tongji Hospital Afﬁliated to Tongji Medical College of Huazhong University of Science and Technology (Wuhan, China) from January 2025 to May 2026.

You may qualify if:

Patients diagnosed with AA, AL, MDS, PMF, or other hematologic diseases according to internationally accepted diagnostic criteria

Sponsors & Collaborators

Tongji Hospital
Otherlead

Study Sites (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

MeSH Terms

Conditions

Thrombocytopenia

Condition Hierarchy (Ancestors)

Blood Platelet DisordersHematologic DiseasesHemic and Lymphatic DiseasesCytopenia

Study Officials

wen
Tongji Hospital Afﬁliated to Tongji Medical College of Huaz- hong University of Science and Technology
PRINCIPAL INVESTIGATOR

Enrollment

103 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Professor of Hematology

Study Record Dates

First Submitted

July 27, 2026

First Posted

August 5, 2026

Study Start

January 1, 2025

Actual (reported)

NCT06521931

A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients

Phase 1Completed

NCT06870851

Predicting Platelet Count From Viscoelastic Testing

Active Not Recruiting

NCT06768619

Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State

Not ApplicableCompleted

NCT06979765

Research for Plasma Biomarkers Associated With Fatigue in Thrombocytopenic Patients

Not ApplicableRecruiting

NCT03838354

A Clinical Trial of Chidamide in the Management of Refractory ITP

Phase 1/2Completed

NCT05087459

Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular Carcinoma

Unknown

Patients who underwent allo-HSCT during the study period

Patients with complete clinical characteristics, transplantation records, and follow-up data

You may not qualify if:

Primary graft failure;
Death before hematopoietic engraftment
Missing key clinical data;(4) Use of thrombopoietin receptor agonists other than romiplostim

Contact the study team to confirm eligibility.

Primary Completion

May 1, 2026

Actual (reported)

Study Completion

July 15, 2026

Actual (reported)

Last Updated

August 5, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT07747246
Data provider: ClinicalTrials.gov
Source updated: 2026-08-05
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:38:53 UTC

Locations

CN(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

Romiplostim Group

Control Group

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations